Lisa Cook sues Trump over firing attempt, emergency hearing set
Entero Therapeutics, Inc. (NASDAQ:ENTO), currently trading at $0.53 with a market capitalization of $2.57 million, announced Tuesday that it has regained compliance with Nasdaq Listing Rule 5620(a) following the successful holding of its annual meeting on June 30. According to a letter received from the Listing Qualifications department of The Nasdaq Stock Market LLC, the company’s compliance status has been restored and the matter is now closed.
The notification to Entero Therapeutics was disclosed in a press release statement and referenced a previous Current Report on Form 8-K filed with the Securities and Exchange Commission on July 2. The company’s shares continue to be listed on the Nasdaq Capital Market.
The information in this article is based on a statement from an SEC filing.
In other recent news, Entero Therapeutics, Inc. announced it has received an extension from the Nasdaq Stock Market to regain compliance with the minimum stockholders’ equity requirement for its continued listing on the Nasdaq Capital Market. This extension allows the company until October 8, 2025, to meet the necessary requirements outlined in Nasdaq Listing Rule 5550(b)(1). The company had previously been notified of non-compliance due to a reported negative stockholders’ equity of $3.87 million as of December 31, 2024, which falls short of the required minimum of $2.5 million. Entero Therapeutics has expressed its intention to submit a compliance plan within the specified timeframe. If the plan is accepted, the company may receive additional time to meet the requirements. However, there is no assurance that the plan will be accepted or that the company will successfully regain compliance. Failure to comply could lead to delisting, although Entero has the option to appeal any delisting determination to a Nasdaq Hearing Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.